Low-Dose Bio-Optimized Berberine Shows Metabolic Benefits in New Crossover Trial

A newly published clinical trial suggests that a bio-optimized berberine ingredient may deliver metabolic health benefits at a fraction of the dose typically required for conventional berberine formulations.¹ “Supplement buyers are seeking drug-like results to experience faster appetite-control, fat loss and lowered glucose, which is creating strong demand for traditional herbal ingredients like berberine,” noted Arunkanth Krishnakumar, PhD, co-founder and director of Zeus Hygia.

The study, published in the August 2026 issue of the International Journal of Clinical Trials, evaluated Metaberine, a berberine ingredient from Zeus Hygia Life Sciences formulated using the company's proprietary BioSOLVE technology. The study authors note that conventional berberine is known for its glucose- and lipid-modulating effects, but its clinical utility has long been limited by poor oral bioavailability (roughly 2%), which necessitates high daily doses of 500–1,500 mg, often divided across multiple administrations, and is associated with gastrointestinal side effects that can undermine compliance.

What Did the Trial Test, and What Did It Find?

The randomized, double-blind, placebo-controlled crossover trial enrolled 36 healthy adults (mean age 39.9 years, BMI 25.8 kg/m²) with fasting glucose in the 100–125 mg/dl range. Participants received either 200 mg/day of Metaberine or placebo for 14 days per period, separated by a seven-day washout.

Researchers assessed fasting and postprandial glucose via a 75 g oral glucose tolerance test (OGTT) at 0, 30, 60, 90 and 120 minutes as the primary outcome, with plasma GLP-1, glucose exposure parameters (AUClast, Cmax) and lipid profile as secondary outcomes.

According to the published results, fasting glucose decreased by 9.08 mg/dl in the Metaberine group compared with 1.36 mg/dl with placebo (p<0.0001), with statistically significant reductions at every postprandial OGTT timepoint. Baseline-corrected glucose AUClast and Cmax decreased by 13.5% and 12.7%, respectively (both p<0.0001). Plasma GLP-1 rose by 29% in the fasting state and 22% postprandially with Metaberine, versus minimal change with placebo (both p<0.0001). The active group also showed reductions in total cholesterol and LDL-C alongside an increase in HDL-C. The trial reported 100% participant retention and no adverse events related to the supplement.

The study authors note that the findings are exploratory given the single-center design, modest sample size and short duration, and call for longer, multicenter trials to confirm effects on HbA1c and insulin sensitivity. Additionally, dietary intake was not quantitatively assessed in the study.

“Collectively, these findings advance understanding of the clinical utility of formulation-enhanced berberine by establishing that BioSOLVE technology can overcome the bioavailability barrier that has historically limited berberine's clinical adoption, enabling metabolic benefits at doses that are both effective and well-tolerated,” the authors conclude.

What Makes Metaberine Different?

According to Zeus Hygia, Metaberine's differentiation stems from BioSOLVE technology, which is designed to improve the properties of water-insoluble actives through a proprietary process that delivers uniform particles with greater surface area and porosity, in turn increasing water solubility, stability, permeability, and functional performance.² The company states that pharmacokinetic evaluations show a multifold increase in area under the concentration–time curve AUC and enhanced peak plasma concentration relative to conventional berberine at equivalent doses, enabling effective supplementation at 200 mg/day while potentially minimizing dose-related gastrointestinal intolerance.

Why Does This Study Matter for the Market?

Zeus Hygia points to broader category tailwinds for the ingredient. Citing NHANES 2023 data, the company notes that 39% of U.S. adults met criteria for metabolic syndrome. It also references FMCG Gurus' Metabolic Health Trends in North America Regional Report from 2024, which found that of the 53% of North American consumers who understand what metabolic health means, 90% recognize its connection to overall health, while only 19% reported satisfaction with their own metabolic health and are actively working to improve it.

The company also says an ongoing 100-subject clinical trial and human pharmacokinetic studies, anticipated for completion by August 2026, are intended to further support Metaberine's safety, efficacy and bioavailability profile.

References

1. Jeyakodi S, Krishnakumar A, Naik DN, Hussain MM, Thomas JV. Metaberine (bio-optimised berberine 200 mg/day) improves metabolic health markers in healthy adults: a randomized, double-blind and placebo-controlled crossover trial. Int J Clin Trials. 2026;13(3):270-282. doi: 10.18203/2349-3259.ijct20262501
2. Zeus Hygia Life Sciences. New study shows Metaberine from Zeus Hygia improves metabolic health factors. Accessed August 12, 2026.